Mushroom Polysaccharide Calms Inflammation by Reshaping Gut Bacteria, Mouse Study Finds

If you have ever wondered whether something as simple as a food compound could calm the kind of low-grade inflammation tied to gut trouble, joint pain, or mood swings, a new mouse and cell study offers a detailed look at one candidate. Researchers isolated a polysaccharide (a long chain of sugar molecules, a common structural component in mushrooms and plants) from an edible mushroom and traced, step by step, how it dialed down inflammatory signaling and reshaped the gut microbiome at the same time. The findings are preclinical, but the mechanism they describe is unusually well mapped for a natural compound.

Key Takeaways

• A polysaccharide called PPp-W, extracted from the mushroom Pleurotus placentodes, suppressed inflammatory markers in immune cells and mice by blocking the NF-kB and MAPK signaling pathways (two of the body's core inflammation switches).
• The compound also reshaped gut bacteria, raising levels of Alistipes and Bacteroides while lowering Desulfovibrio and Lactobacillus, and appeared to act partly through a receptor called BDKRB2.
• Every result comes from lab dishes and mice; there is no human data yet, and no mainstream press has covered this specific paper.
• The compound is not available as a supplement, and the study does not establish any diet or product as an anti-inflammatory treatment.

Mushroom Polysaccharide PPp-W Suppresses Inflammatory Signaling

Researchers found that a polysaccharide named PPp-W, drawn from the mushroom species Pleurotus placentodes, suppressed key markers of inflammation in both immune cells and mice by interrupting two of the body's central inflammatory signaling pathways, NF-kB and MAPK (nuclear factor kappa B and mitogen-activated protein kinase, two interlinked protein cascades that turn on inflammatory genes). In a study published in the Journal of Functional Foods, the compound cut secretion of the inflammatory signaling proteins IL-6 and TNF-alpha in immune cells exposed to a bacterial toxin, and it blunted the phosphorylation, or chemical activation, of the p65, p38, JNK, and ERK proteins that make up the NF-kB and MAPK cascades. P. placentodes itself is a recently domesticated mushroom species, first cultivated by China's Institute of Microbiology, and the researchers note it is unusually rich in protein (about 30 grams per 100 grams) and polysaccharides (about 7.5 grams per 100 grams) compared with common cultivated mushrooms.

Chronic Inflammation Behind IBD, IBS, and Autoimmune Disease

Persistent, low-grade inflammation is a shared driver behind a wide range of conditions people actively manage day to day, including inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), rheumatoid arthritis, and metabolic conditions like type 2 diabetes, which is why compounds that interrupt inflammatory signaling draw research interest well beyond any one disease. The NF-kB and MAPK pathways this study targets are the same general signaling machinery implicated across those conditions, and gut bacteria composition has been separately linked to IBD and IBS severity in prior research, as summarized in this review of mushroom polysaccharides and gut microbiota. That overlap is what makes a compound acting on both inflammatory signaling and gut bacteria composition at once notable, even though this particular study did not test any of those diseases directly.

How Researchers Tested PPp-W in Cells and Mice

The team ran two linked experiments to establish the mechanism. First, they exposed RAW264.7 mouse macrophages (a standard immune cell line) to a bacterial toxin called LPS (lipopolysaccharide, a fragment of bacterial cell walls that reliably triggers inflammation in lab models) alongside varying doses of PPp-W, and measured inflammatory markers by ELISA and protein activation by Western blot. Second, they moved into live animals: 60 male mice were split into six groups of 10, receiving either a saline control, LPS alone to induce inflammation, a standard anti-inflammatory drug (dexamethasone) as a positive control, or one of three daily doses of PPp-W (200, 100, or 50 milligrams per kilogram) for 18 days, with LPS injections added on the final three days to trigger inflammation. The researchers then layered on proteomics (a systematic scan of protein activity, which identified 7,323 proteins in spleen tissue and found 585 that shifted significantly with high-dose PPp-W treatment) and 16S rDNA gene sequencing of gut bacteria from the mice's intestinal contents, giving the study more mechanistic depth than a typical single-endpoint animal experiment.

What This Means for People Managing Gut Inflammation

For someone whose IBS, IBD, or another inflammation-linked condition traces back to gut health, this study is best read as an early mechanistic clue rather than a signal to change anything about diet or supplements. The specific finding worth watching is that PPp-W appears to work partly by suppressing a receptor called BDKRB2 (bradykinin receptor B2, a cell-surface protein that, when active, promotes inflammation through NF-kB and MAPK signaling, a link corroborated in separate human cell research on the same receptor); the researchers confirmed this by silencing the BDKRB2 gene directly in immune cells and seeing the same anti-inflammatory effect. Alongside that, the mice given PPp-W showed a shift in gut bacteria toward more Alistipes and Bacteroides, two genera separately reported to correlate with lower gut inflammation in other studies, including this review on Alistipes and inflammation. None of that establishes P. placentodes, mushroom supplements broadly, or PPp-W itself as a treatment for any human condition, and nothing here should be read as dietary or medical advice.

Key Limitations: No Human Trials Yet

The most important caveat is straightforward: every result in this study comes from mouse experiments and cultured immune cells, and PPp-W has not been tested in people. Mouse inflammation models, even ones designed to mimic human physiology, do not always predict how a compound will behave in a human gut, at human doses, over a human lifespan. The gut bacteria changes and the BDKRB2 mechanism were also identified in the same set of experiments rather than confirmed independently by a second research group, so replication is an open question. There is also no evidence yet on whether eating P. placentodes as food, rather than a purified extract dosed at specific milligram-per-kilogram levels, would produce anything close to these effects, and this specific paper has not drawn attention from mainstream science press.

What Comes Next for PPp-W Research

The same research group has previously shown that PPp-W survives digestion through simulated saliva, stomach acid, and intestinal fluid largely intact, only breaking down once gut bacteria ferment it, which is part of why they suspect its effects run through the microbiome rather than direct absorption. The logical next steps would be dose-response work to find whether lower, more food-realistic amounts still produce an effect, independent replication of the BDKRB2 and gut bacteria findings, and eventually safety and pharmacokinetic studies that could support human trials, none of which this paper reports having started.

Common Questions

What is Pleurotus placentodes? It is a recently domesticated edible mushroom species, first cultivated by the Institute of Microbiology at the Chinese Academy of Sciences, and this study is among the first to investigate a specific bioactive compound isolated from it.

Does this mean eating mushrooms reduces inflammation? Not based on this study. The researchers used a purified polysaccharide extract at specific doses in mice and cells, not whole mushrooms eaten as food, so the results do not translate directly into dietary advice.

Is PPp-W available as a supplement? No. It is a research compound isolated and studied in a laboratory setting, not a commercially available product.

What would need to happen before this could apply to people? Independent replication of the mechanism, dose-response studies, and eventually controlled human trials, none of which have been reported yet.

References

1. Zhenhua Yin, Lin Guo, Senye Wang, et al. (2026). Anti-inflammatory mechanism of polysaccharide from Pleurotus placentodes by modulating proteins, gut microbiota, and metabolism. Journal of Functional Foods. https://doi.org/10.1016/j.jff.2026.107472
2. Jiahui Zhao, Yixin Hu, Chao Qian, et al. (2023). The Interaction between Mushroom Polysaccharides and Gut Microbiota and Their Effect on Human Health: A Review. Biology. https://doi.org/10.3390/biology12010122
3. Erika Terzuoli, Stefania Meini, Paola Cucchi, et al. (2014). Antagonism of Bradykinin B2 Receptor Prevents Inflammatory Responses in Human Endothelial Cells by Quenching the NF-kB Pathway Activation. PLoS ONE. https://doi.org/10.1371/journal.pone.0084358
4. Bianca J. Parker, Pamela A. Wearsch, Alida C. M. Veloo, Alex Rodriguez-Palacios (2020). The Genus Alistipes: Gut Bacteria With Emerging Implications to Inflammation, Cancer, and Mental Health. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2020.00906